Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune disease treatments, has granted its new Chief Executive Officer Jean-Paul Kress a significant stock option award. The inducement grant, approved on June 26, 2025, includes options to purchase 83,296,638 shares of common stock at an exercise price of $0.89 per share.
The stock option, granted under the Vor Biopharma Inc. 2023 Inducement Plan, has a ten-year term and follows a four-year vesting schedule. The vesting includes a 25% cliff after the first year, followed by monthly vesting over the subsequent 36 months, contingent on Dr. Kress's continued employment.
Vor Bio (Nasdaq: VOR), un'azienda biotecnologica in fase clinica specializzata in trattamenti per malattie autoimmuni, ha assegnato al suo nuovo Amministratore Delegato Jean-Paul Kress un significativo premio in opzioni su azioni. La concessione, approvata il 26 giugno 2025, prevede opzioni per l'acquisto di 83.296.638 azioni ordinarie al prezzo di esercizio di 0,89 $ per azione.
L'opzione su azioni, concessa nell'ambito del Vor Biopharma Inc. 2023 Inducement Plan, ha una durata di dieci anni e segue un piano di maturazione quadriennale. La maturazione prevede un cliff del 25% dopo il primo anno, seguito da una maturazione mensile nei successivi 36 mesi, subordinata alla continuazione dell'impiego del dottor Kress.
Vor Bio (Nasdaq: VOR), una empresa biotecnol贸gica en etapa cl铆nica enfocada en tratamientos para enfermedades autoinmunes, ha otorgado a su nuevo Director Ejecutivo Jean-Paul Kress una importante concesi贸n de opciones sobre acciones. La concesi贸n inducida, aprobada el 26 de junio de 2025, incluye opciones para comprar 83,296,638 acciones ordinarias a un precio de ejercicio de $0.89 por acci贸n.
La opci贸n sobre acciones, otorgada bajo el Plan de Inducci贸n de Vor Biopharma Inc. 2023, tiene un plazo de diez a帽os y sigue un calendario de adquisici贸n de derechos de cuatro a帽os. La adquisici贸n incluye un cliff del 25% despu茅s del primer a帽o, seguido de una adquisici贸n mensual durante los siguientes 36 meses, condicionado a la continuidad laboral del Dr. Kress.
Vor Bio (雮橃姢雼�: VOR)電� 鞛愱皜氅挫棴 歆堩櫂 旃橂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 靸� 斓滉碃瓴届榿鞛�(CEO)鞚� Jean-Paul Kress鞐愱矊 靸侂嫻頃� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 2025雲� 6鞗� 26鞚� 鞀轨澑霅� 鞚� 鞚胳劶韹半笇 攵�鞐姅 83,296,638欤�鞚� 氤错喌欤茧ゼ 欤茧嫻 $0.89鞚� 頄夓偓臧�瓴╈溂搿� 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞚� 韽暔頃╇媹雼�.
Vor Biopharma Inc. 2023 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 攵�鞐悳 鞚� 欤检嫕毵れ垬靹犿儩甓岇潃 10雲勱皠 鞙犿毃頃橂┌ 4雲勱皠鞚� 氩犾姢韺� 鞀れ紑欷勳潉 霐半雼堧嫟. 氩犾姢韺呾潃 觳� 頃� 頉� 25% 韥措Μ頂�鞕� 攴� 頉� 36臧滌洈 霃欖晥 鞗旊硠 氩犾姢韺呾溂搿� 甑劚霅橂┌, Kress 氚曥偓鞚� 歆�靻嶌爜鞚� 瓿犾毄鞚� 臁瓣贝鞛呺媹雼�.
Vor Bio (Nasdaq : VOR), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les traitements des maladies auto-immunes, a accord茅 脿 son nouveau Directeur G茅n茅ral Jean-Paul Kress une attribution importante d'options d'achat d'actions. Cette attribution incitative, approuv茅e le 26 juin 2025, comprend des options d'achat de 83 296 638 actions ordinaires 脿 un prix d'exercice de 0,89 $ par action.
Les options d'achat, accord茅es dans le cadre du Plan d'Incitation 2023 de Vor Biopharma Inc., ont une dur茅e de dix ans et suivent un calendrier d'acquisition des droits sur quatre ans. L'acquisition comprend un cliff de 25 % apr猫s la premi猫re ann茅e, suivi d'une acquisition mensuelle sur les 36 mois suivants, sous r茅serve de la poursuite de l'emploi du Dr Kress.
Vor Bio (Nasdaq: VOR), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Autoimmunerkrankungen spezialisiert hat, hat seinem neuen Chief Executive Officer Jean-Paul Kress eine bedeutende Aktienoptionszuteilung gew盲hrt. Die am 26. Juni 2025 genehmigte Anreizzuteilung umfasst Optionen zum Kauf von 83.296.638 Stammaktien zu einem Aus眉bungspreis von 0,89 $ pro Aktie.
Die unter dem Vor Biopharma Inc. 2023 Inducement Plan gew盲hrte Aktienoption hat eine Laufzeit von zehn Jahren und folgt einem vierj盲hrigen Vesting-Plan. Das Vesting beinhaltet einen 25% Cliff nach dem ersten Jahr, gefolgt von monatlichem Vesting 眉ber die darauffolgenden 36 Monate, abh盲ngig von der fortgesetzten Anstellung von Dr. Kress.
- None.
- Significant potential dilution with 83,296,638 shares in options granted
- Low share price of $0.89 suggests challenging market conditions
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company鈥檚 Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio鈥檚 common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the 鈥淚nducement Plan鈥�).
The stock option has a ten-year term and an exercise price of
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
FAQ
How many stock options were granted to Vor Bio's new CEO?
What is the vesting schedule for VOR CEO's stock options?
When was Jean-Paul Kress appointed as Vor Bio's CEO?
What is the exercise price of VOR's CEO inducement grant?
How long do the VOR CEO stock options last?
